Donor‐specific human leukocyte antigen antibodies of the immunoglobulin G3 subclass are associated with Chronic rejection and graft loss after liver transplantation

Hugo Kaneku, Jacqueline G. O'Leary, Michiko Taniguchi, Brian M. Susskind, Paul I. Terasaki, Göran B. Klintmalm – 16 April 2012 – In a previous study, we found that 92% of patients with chronic rejection had donor‐specific human leukocyte antigen antibodies (DSAs), but surprisingly, 61% of comparator patients without rejection also had DSAs. We hypothesized that immunoglobulin G (IgG) subclasses were differentially distributed between the 2 groups.

Recruitment mechanisms of primary and malignant B cells to the human liver

Shishir Shetty, Tony Bruns, Christopher J. Weston, Zania Stamataki, Ye H. Oo, Heather M. Long, Gary M. Reynolds, Guy Pratt, Paul Moss, Sirpa Jalkanen, Stefan G. Hubscher, Patricia F. Lalor, David H. Adams – 16 April 2012 – B cells are present within chronically inflamed liver tissue and recent evidence implicates them in the progression of liver disease. In addition, a large proportion of hepatic lymphomas are of B‐cell origin.

Hepatic steatosis and steatohepatitis in human immunodeficiency virus/hepatitis C virus–coinfected patients

Juan Macías, Juan Berenguer, Miguel A. Japón, José A. Girón‐González, Antonio Rivero, Luis F. López‐Cortés, Ana Moreno, Manuel Márquez, José A. Iribarren, Enrique Ortega, Pilar Miralles, Nicolás Merchante, Juan A. Pineda – 16 April 2012 – Hepatic steatosis (HS) is frequent in human immunodeficiency virus (HIV)‐ and hepatitis C virus (HCV)‐coinfected patients. Antiretroviral therapy (ART) and metabolic alterations could induce HS. However, a protective effect of ART has been reported in a paired biopsy study.

Is it safe to use a liver graft from a chagas disease–seropositive donor in a human immunodeficiency virus–positive recipient? A case report addressing a novel challenge in liver transplantation

Nicolás Goldaracena, Michelle Mayer Wolf, Emilio Quiñonez, Margarita Anders, Ricardo Mastai, Lucas McCormack – 16 April 2012 – This is the first report presenting a human immunodeficiency virus (HIV)–positive patient with fulminant hepatic failure receiving a liver graft from a Chagas disease–seropositive deceased donor.

Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis

Christopher Savard, Erica V. Tartaglione, Rahul Kuver, W. Geoffrey Haigh, Geoffrey C. Farrell, Savitha Subramanian, Alan Chait, Matthew M. Yeh, LeBris S. Quinn, George N. Ioannou – 16 April 2012 – The majority of patients with nonalcoholic fatty liver disease (NAFLD) have “simple steatosis,” which is defined by hepatic steatosis in the absence of substantial inflammation or fibrosis and is considered to be benign.

Early regeneration of the remnant liver volume after right hepatectomy for living donation: A multiple regression analysis

Salvatore Gruttadauria, Vishal Parikh, Duilio Pagano, Fabio Tuzzolino, Davide Cintorino, Roberto Miraglia, Marco Spada, Giovanbattista Vizzini, Angelo Luca, Bruno Gridelli – 14 April 2012 – Early liver regeneration was studied in a series of 70 patients who underwent right hepatectomy for living donation between November 2004 and January 2010. Liver regeneration was evaluated with multidetector computed tomography (MDCT) at a mean of 61.07 days after surgery.

Clostridium difficile infection in hospitalized liver transplant patients: A nationwide analysis

Muhammad Ali, Ashwin N. Ananthakrishnan, Shahryar Ahmad, Nilay Kumar, Gagan Kumar, Kia Saeian – 14 April 2012 – The incidence of Clostridium difficile infection (CDI) is increasing among hospitalized patients. Liver transplantation (LT) patients are at higher risk for acquiring CDI. Small, single‐center studies (but no nationwide analyses) have assessed this association. We used the Nationwide Inpatient Sample of the Healthcare Cost and Utilization Project (2004‐2008) for this retrospective, cross‐sectional study.

Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: New evidence on the potential therapeutic mechanism

Claudia O. Zein, Rocio Lopez, Xiaoming Fu, John P. Kirwan, Lisa M. Yerian, Arthur J. McCullough, Stanley L. Hazen, Ariel E. Feldstein – 13 April 2012 – Pentoxifylline (PTX) improved the histological features of nonalcoholic steatohepatitis (NASH) in a recent randomized placebo‐controlled trial. However, the underlying mechanism responsible for the beneficial effects of PTX in NASH remains unidentified. A key role of lipid oxidation in the pathogenesis and progression of NASH has been established. PTX is known to decrease free‐radical‐mediated oxidative stress and inhibit lipid oxidation.

Subscribe to